key: cord-0794256-k4puoc3z
authors: Kulkarni, Rakesh; Chen, Wen-Ching; Lee, Ying; Kao, Chi-Fei; Hu, Shiu-Lok; Ma, Hsiu-Hua; Jan, Jia-Tsrong; Liao, Chun-Che; Liang, Jian-Jong; Ko, Hui-Ying; Sun, Cheng-Pu; Lin, Yin-Shoiou; Wang, Yu-Chiuan; Wei, Sung-Chan; Lin, Yi-Ling; Ma, Che; Chao, Yu-Chan; Chou, Yu-Chi; Chang, Wen
title: Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters
date: 2021-09-09
journal: PLoS One
DOI: 10.1371/journal.pone.0257191
sha: a5d4cfa852547c69eedecef846f0bc42cc5a21c7
doc_id: 794256
cord_uid: k4puoc3z

COVID-19 in humans is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that belongs to the beta family of coronaviruses. SARS-CoV-2 causes severe respiratory illness in 10–15% of infected individuals and mortality in 2–3%. Vaccines are urgently needed to prevent infection and to contain viral spread. Although several mRNA- and adenovirus-based vaccines are highly effective, their dependence on the “cold chain” transportation makes global vaccination a difficult task. In this context, a stable lyophilized vaccine may present certain advantages. Accordingly, establishing additional vaccine platforms remains vital to tackle SARS-CoV-2 and any future variants that may arise. Vaccinia virus (VACV) has been used to eradicate smallpox disease, and several attenuated viral strains with enhanced safety for human applications have been developed. We have generated two candidate SARS-CoV-2 vaccines based on two vaccinia viral strains, MVA and v-NY, that express full-length SARS-CoV-2 spike protein. Whereas MVA is growth-restricted in mammalian cells, the v-NY strain is replication-competent. We demonstrate that both candidate recombinant vaccines induce high titers of neutralizing antibodies in C57BL/6 mice vaccinated according to prime-boost regimens. Furthermore, our vaccination regimens generated T(H)1-biased immune responses in mice. Most importantly, prime-boost vaccination of a Syrian hamster infection model with MVA-S and v-NY-S protected the hamsters against SARS-CoV-2 infection, supporting that these two vaccines are promising candidates for future development. Finally, our vaccination regimens generated neutralizing antibodies that partially cross-neutralized SARS-CoV-2 variants of concern.

Introduction (MVA5/MVA1), mice were primed i.m. with 5x10 7 PFU/animal of MVA-S virus and boosted with 1x10 7 PFU/animal of MVA-S. For the second regimen, (vNY1/MVA1), mice were primed with 1x10 7 PFU/animal of v-NY-S by means of tail scarification (t.s.) and then boosted i.m. with 1x10 7 PFU/animal of MVA-S. For the third regimen, (vNY5/MVA1), mice were primed with v-NY-S at a higher titer of 5x10 7 PFU/mouse by t.s. and then boosted i.m. with 1x10 7 PFU/animal of MVA-S. For each regimen, the mice were primed at day 0 and primary (1˚) sera were collected 4 weeks later. These mice were then rested for 3 days, boosted, and then secondary (2˚) sera were drawn 2 weeks later. In some experiments, spleens were harvested 4 weeks after boosting for T cell and cytokine analyses. The t.s. site of vaccinated mice healed well and the mice remained healthy without any loss of body weight (S1 Fig). 1˚and 2s era were collected from mice and flow cytometry revealed that they recognized SARS-CoV-2 S protein expressed from recombinant S-BAC baculovirus ( Fig 2B) . Quantification (Fig 2C) confirmed that anti-spike antibodies were specifically generated after primary immunization and that antibody titers were significantly enhanced after vaccine boosting. Mice primed with v-NY-S presented higher levels of anti-spike antibody compared to those primed with MVA-S ( Fig 2C) . Immunoblot analyses (Fig 2D) also revealed anti-spike antibody reactivity to recombinant S protein, consistent with our FACS data ( Fig 2C) . We tested the neutralizing activity of 2˚sera using SARS-CoV-2 spike pseudotyped virus ( Fig 2E, panel i) and SARS-CoV-2 virus (Fig 2E, panel ii) . Neutralization activity is presented as the reciprocal dilution of serum required for 50% inhibition of virus infection (ND 50 ). Our results show that all three regimens successfully generated high titers of neutralizing antibodies that inhibited SARS-CoV-2 S protein-mediated virus entry in both infection systems. Finally, we tested if our prime-boost vaccination regimens induced long-lasting antibody responses by comparing mouse sera collected at 0.5 and 4.5 months after the MVA5/MVA1 and vNY1/MVA1 regimens. Sera taken 4.5 months after boosting still contained 60-80% of spike-specific antibodies, as revealed by FACS analyses (Fig 2F) , and a pseudotyped SARS-CoV-2 virus infection assay demonstrated that they retained comparable neutralization activity to sera at 0.5 months (Fig 2G) , indicating these two vaccination regimens can elicit long-lived anti-spike antibody responses that have been shown to correlate with protection against SARS-CoV-2.

IFN-γ-producing T H 1 cells promote a B-cell class switch towards IgG2a/IgG2c, whereas IL-4-producing T H 2 cells promote a class switch towards IgG1 [49, 50] . Therefore, a ratio of IgG2c (or IgG2a) to IgG1 >1 is a good indicator of a T H 1-biased immune response, which is important for pathogen clearance. Accordingly, we used ELISA to measure levels of the IgG2c and IgG1 isotypes of anti-spike antibodies in C57BL/6 mouse sera collected after vaccination regimens ( Fig 3A) . All three vaccination regimens induced production of the IgG2c and IgG1 isotypes ( Fig 3A) and with IgG2c/IgG1 ratios > 1 (Fig 3B) , suggesting they had elicited a T H 1-biased immune response. We further in vitro-stimulated splenocytes from vaccinated mice with a SARS-CoV-2 spike peptide pool and then counted cells secreting T H 1 cytokines (IL−2, IFN-γ and TNF-α) and T H 2 cytokines (IL-4 and IL-6) ( Fig 3C) [51, 52] . Consistently, we found that more cells secreted TNF-α and IFN-γ than IL-4 and IL-6 ( Fig 3C) , supporting that our three vaccination regimens triggered a T H 1-biased response [51, 52] . Furthermore, we investigated if our immunization regimens generated T effector memory (Tem) cells that are known to play a critical role in immune protection against secondary viral infections in lung tissue [53] . Splenocytes isolated from mice 4 weeks after vaccination regimens were incubated with a SARS-CoV-2 spike peptide pool for 2 h and then analyzed by flow cytometry (Fig 3D &  3E ), which revealed that all three regimens resulted in significantly increased numbers of CD8 + Tem cells (Fig 3D) , but not CD4 + Tem cells (Fig 3E) , in spleen tissue.

C57BL/6 mice are not susceptible to SARS-CoV-2 infection, whereas Syrian hamsters serve as an appropriate animal model of respiratory infection by SARS-CoV-2 in human [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] . We subjected Syrian hamsters to the same prime-boost vaccination regimens, i.e., MVA5/MVA1, vNY1/MVA1 and vNY5/MVA1 (Fig 4A) as applied to mice (Fig 2A) , except that we used a skin scarification inoculation approach for hamsters. A small scar formed at the immunization site, which healed within two weeks (S2A Fig) , and the immunized hamsters remained healthy any did not exhibit weight loss (S2B Fig) . Primary and secondary sera collected from these immunized hamsters specifically recognized SARS-CoV-2 S protein expressed on cell surfaces ( Fig 4B) . Quantification of all hamster sera by FACS demonstrated that boosting enhanced anti-spike antibody titers (Fig 4C) , which was confirmed by immunoblotting ( Fig 4D) . Importantly, all three vaccination regimens generated anti-spike antibodies with high neutralization activity in both pseudotyped SARS-CoV-2 virus (Fig 4E, panel i) and live SARS-CoV-2 virus infection assays (Fig 4E, panel ii) . Taken together, these data show that, as observed for mice, our vaccination regimens generated high antibody titers in hamsters that neutralized SARS-CoV-2 infection.

Next, we performed challenge experiments in hamsters 2 weeks after vaccine boosting by intranasally (i.n) inoculating 1x10 5 PFU/animal of SARS-CoV-2 virus into each hamster and then measuring changes in body weight till 3 d.p.i. (Fig 5A) . Control hamsters (immunized with a PBS placebo) presented minor but detectable weight loss at 3 d.p.i., whereas those subjected to our vaccination regimens presented no obvious weight loss (Fig 5B) . Previous studies showed that SARS-CoV-2 infection of Syrian hamsters results in virus replication in lung tissue and that virus titers often peaked from 2-4 d.p.i. and gradually cleared by 7 d.p.i. [54, 56, 58, [66] [67] [68] [69] [70] . Therefore, we sacrificed hamsters at 3 d.p.i. and then measured SARS-CoV-2 virus titers in their lungs (Fig 5C) . None of the MVA5/MVA1-or vNY1/MVA1-vaccinated hamsters presented detectable levels of SARS-CoV-2 virus in their lung tissue, whereas virus titers of up to~4x10 6 TCID 50 were detected in the lungs of the placebo group ( Fig 5C) . Moreover, no virus was detected in nine vNY5/MVA1-immunized hamsters and only one such animal . Primary and secondary sera from immunized mice recognized SARS-CoV-2 S protein on cell surfaces. Mouse sera collected 4 weeks after priming (1˚sera) and 2 weeks after boosting (2˚sera) were assessed for SARS-CoV-2-specific IgG antibodies by flow cytometry using SF9 cells infected with either S-BAC (red line) or WT-BAC (black line). A single representative serum is shown in each histogram. (C). Quantification of anti-spike antibody titers in 1˚and 2˚sera from mice (as shown in B) using the mean fluorescence intensity (MFI) value from FACS. Numbers of mice for 1˚and 2˚sera collection are identical: PBS vs. PBS/PBS control (n = 3); MVA5 vs. MVA5/MVA1 (n = 5); vNY1 vs. vNY1/ MVA1 (n = 5), and vNY5 vs. v-NY5/MVA1 (n = 5). Data are represented as mean ± SD. �� p<0.01; ��� p<0.001; ���� p<0.0001. (D). Immunoblot analyses of recombinant SARS-CoV-2 S protein using 1˚and 2˚sera (1:100) from immunized mice. A single representative serum is shown in each blot. (E). Neutralization assays of 2˚sera collected from vaccinated mice using (i) Pseudovirus and (ii) SARS-CoV-2 virus infection: PBS/PBS control (n = 3); MVA5MVA1 (n = 5); vNY1/MVA1 (n = 5); and vNY5/MVA1 (n = 5). The dotted line represents assay limits of detection. � p<0.05; �� p<0.01. (F). Quantification of anti-spike antibodies in mouse sera collected at 0.5 and 4.5 months after vaccination regimens using SF9 cells infected with WT-BAC or S-BAC. � p<0.05; �� p<0.01; ���� p<0.0001. (G). Pseudovirus neutralization assay using mouse sera collected at 0.5 months and 4.5 months after vaccination regimens: PBS/PBS control (n = 3); MVA5/MVA1 (n = 5); and vNY1/ MVA1 (n = 5). ns-not significant. � p<0.05. The dotted line represents assay limits of detection.

https://doi.org/10.1371/journal.pone.0257191.g002 End-point titers of SARS-CoV-2 spikespecific IgG2C and IgG1 antibodies in mouse sera collected 2 weeks after vaccination regimens. ns-not significant; �� p<0.01; ���� p<0.0001. (B). End-point titer IgG2C/ IgG1 ratio calculated based on data from (A) (n = 5 for each group). (C). ELISpot analyses of mouse splenocytes collected 4 weeks after vaccination regimens for their expression of IL-2, IFN-γ, TNF-α, IL4 and IL6 cytokines (n = 5 for each group). Data represented as mean ± SEM. SFC-spot-forming cells. � p<0.05; �� p<0.01; ��� p<0.001. (D & E). SARS-CoV-2 spike-specific CD8 + (in D) and CD4 + (in E) T effector memory cells (CD44 + CD62L -) in splenocytes, as detected by flow cytometry (n = 5 for each group). Data represented as mean ± SD. ns-not significant; ��� p<0.001; ���� p<0.0001.

https://doi.org/10.1371/journal.pone.0257191.g003

Vaccinia virus as a SARS-CoV-2 vaccine vector . Primary and secondary sera from immunized hamsters recognized SARS-CoV-2 S protein on cell surfaces. Hamster sera collected 4 weeks after priming (1˚sera) and 2 weeks after boosting (2˚sera) were assessed for SARS-CoV-2-specific IgG antibodies by flow cytometry using SF9 cells infected with either S-BAC (red line) or WT-BAC (black line). A single representative serum is shown in each histogram. (C). Quantification of anti-spike antibody titers in 1˚and 2˚sera from hamsters in B, using the mean fluorescence intensity (MFI) value from FACS. Numbers of presented residual amounts of virus (< 0.1% of the mean virus titer of the placebo group) ( Fig  5C) .

We further explored the impact of our MVA5/MVA1 regimen at 7 d.p.i. (Fig 5D) . The weight loss of the placebo group was even more pronounced at 7 d.p.i. than at 3 d.p.i. (~10-15%), whereas that of MVA5/MVA1-immunized hamsters remained unchanged (Fig 5E) . When we harvested lungs from immunized or placebo hamsters at 7 d.p.i. and measured SARS-CoV-2 virus titers and viral RNA levels, we found that no virus was detected in any of the hamsters (S3 Fig), but~0 6 copies of viral RNA were detected in the lungs of the placebo group, whereas only~10 2 copies were detected in MVA5/MVA1-immunized hamsters ( Fig  5F) .

To further validate our findings, we removed the lungs of experimental hamsters at 3 and 7 d.p.i. and processed them for histological examination (Fig 6) . The lungs of placebo-infected hamsters at 3 d.p.i. presented diffuse congestion, shrinking of alveoli, hemorrhaging, and mononuclear cell infiltration ( Fig 6A, open arrowheads) . Moreover, bronchiolar epithelia vacuolization, necrosis and inflammatory exudates were also observed, and there was pronounced vasculitis and/or endothelialitis (Fig 6A, black arrows) involving both medium and small blood vessels disrupted by a mixture of immune infiltrates. Immunostaining with an antibody against SARS-CoV-2 nucleocapsid (NP) protein revealed some areas of peribronchiolar immunoreactivity (Fig 6A) , mainly in the pneumocytes and less commonly in bronchiolar epithelial cells. Interestingly, despite the severe endothelial destruction observed by H&E staining, the SARS-CoV-2 NP antibody we deployed did not detect any positive viral-protein signal in the blood vessels of these placebo-infected hamsters. In contrast to the striking bronchointerstitial pneumonia observed in placebo-infected hamsters, there was only minimal to mild lung inflammation at 3 d.p.i. in the hamster groups subjected to the three vaccination regimens and SARS-CoV-2 NP protein signal was barely detectable (Fig 6B-6D) .

We also examined the lung tissues of hamsters of the placebo and MVA5/MVA1 groups at 7 d.p.i. (Fig 6E & 6F) . Profound type II pneumocyte hyperplasia ( Fig 6E, open arrows) was observed for the placebo-infection group, accompanied by mild to moderate neutrophilic infiltrate and numerous megakaryocytes centered on an obliterated bronchiole. Immunohistochemistry revealed weak but positive anti-NP antibody signal in pneumocytes at the periphery of bronchiole-centered lesions of placebo-infected hamsters ( Fig 6E) . In contrast, the lungs of the MVA5/MVA1-infected group presented a less inflammatory phenotype at 7 d.p.i. and barely detectable anti-NP signal. Thus, taken together, our prime-boost vaccination regimens prevent SARS-CoV-2 viral spread in lung tissues and reduce inflammation and lung pathology.

We wished to establish if single-dose immunization with recombinant v-NY-S virus could provide protection against SARS-CoV-2 in Syrian hamsters. Hamsters were immunized with PBS (placebo), 1x10 7 or 5x10 7 PFU/animal of v-NY-S by skin scarification and then sera were collected 2 weeks later ( Fig 7A) . The sera were subjected to a SARS-CoV-2 pseudovirus neutralization assay, which showed that priming with v-NY-S alone generated neutralizing antibodies hamsters for 1˚and 2˚sera collection are identical: PBS vs. PBS/PBS control (n = 15); MVA5 vs. MVA5/MVA1 (n = 10); vNY1 vs. vNY1/MVA1 (n = 10), and vNY5 vs. v-NY5/MVA1 (n = 10). Data are represented as mean ± SD. ���� p<0.0001. (D). Immunoblots of 1˚and 2˚sera (1:20) from immunized hamsters using recombinant SARS-CoV-2 S protein. A single representative serum is shown in each blot. (E). Neutralization assays of 2˚sera collected from vaccinated hamsters using (i) pseudovirus and (ii) SARS-CoV-2 virus infection: PBS control (n = 12); MVA5/MVA1 (n = 10); vNY1/MVA1 (n = 10); and vNY5/MVA1 (n = 10). The dotted line represents assay limits of detection. ��� p<0.001; ���� p<0.0001.

https://doi.org/10.1371/journal.pone.0257191.g004

Vaccinia virus as a SARS-CoV-2 vaccine vector (Fig 7B) . Then we performed challenge experiments and monitored SARS-CoV-2 virus titers in lungs at 3 d.p.i. (Fig 7C) . Virus titers were~10 6 PFU/animal in the placebo-infected group, but virus titers were >100-fold lower in hamsters subjected to single immunization with v-NY-S at either dosage (1x10 7 or 5x10 7 PFU/animal), showing that single immunization had already provided partial protection against SARS-CoV-2 infection. Upon removing lungs for histological examination, we observed that the placebo-infected group presented a severe pathological phenotype including diffuse congestion, shrinking of alveoli, hemorrhaging, and mononuclear cell infiltration ( Fig  7D, open arrowheads) . Moreover, immunostaining for SARS-CoV-2 NP protein also revealed widespread peribronchiolar immunoreactivity (Fig 7D, arrowheads) in the lungs of the placebo group. In contrast, the lung pathology of the vNY1-infected ( Fig 7E) and vNY5-infected ( Fig 7F) groups was much milder than observed for the placebo-infected group, displaying lower immune cell infiltration, rare epithelial degeneration and an absence of vasculitis/ endothelialitis. Viral NP immune signal in lung tissues was also significantly lower in the vNY1 and vNY5 groups relative to the placebo group (rightmost panels in Fig 7E & 7F ).

Recently, circulation of new SARS-CoV-2 variants of concern (VOC) has become prevalent, entailing a risk of increasing resistance to the neutralizing antibodies generated by SARS-CoV-2 vaccines. Accordingly, we used pseudotyped SARS-CoV-2 virus neutralization assays to test sera from our prime-boost vaccinated mice for their ability to cross-neutralize SARS-CoV-2 variants (Fig 8) . Although statistical analyses did not reveal a significant neutralization difference among the three immunization regimens to each variant, the mean neutralization titers of the α and γ variants were similar to that of the wild type whereas the mean titers of β, B.1.617 and δ variants appeared much lower than the wild type ( Fig 8A) . For sera generated according to each regimen ( Fig 8B-8D ), we divided the value of ND 50 for wild type by that of each variant to obtain the fold decrease in neutralization for each variant relative to wild type (Fig 8B-8D ). We noticed that vNY5/MVA1 regimen maintained the least decrease of neutralization towards all variants ( Fig 8D) followed by vNY1/MVA1( Fig 8C) and MVA5/MVA1 ( Fig  8B) . Overall, antibodies from mice vaccinated with the heterologous prime-boost regimens, vNY1/MVA1 and vNY5/MVA1, appeared to display better cross-neutralization against different variants than those with the homologous prime-boost regimen (MVA5/MVA1).

Our current regimens comprise both homologous (MVA5/MVA1) and heterologous (vNY1/ MVA1 and vNY5/MVA1) prime-boost combinations, with these latter generating strong and long-lasting neutralizing antibody responses ( Fig 2F) . We wanted to explore other prime- (Fig 2C) , prime-boosting with a homologous vNY1/vNY1 strategy did not increase anti-spike antibody titers after boosting ( Fig 9A) . We rationalize that homologous prime-boosting with a replicating virus such as v-NY-S is not a good immunization strategy. Interestingly, heterologous priming with v-NY-S at 1x10 7 PFU, followed by a boost with 5 μg recombinant spike protein (rS) plus adjuvant, enhanced antispike antibody titers ( Fig 9A) and neutralizing activity ( Fig 9B) . In addition, we compared the route of priming between skin scarification (vNY1/MVA1) and intranasal inoculation (vNY0.1/MVA1) for v-NY-S and found that the latter route generated higher anti-spike antibody levels ( Fig 9A) and neutralizing activity ( Fig 9B) with only 1/10 of virus inoculum. These data are very encouraging and will aid in future vaccination strategies. Discussions are ongoing as to whether heterologous prime-boosting of COVID vaccines elicits more potent immune responses than a homologous prime-boost strategy [71] [72] [73] . We argue that mix-and-match vaccination strategies are an important consideration for designing the next generation of SARS-CoV-2 vaccines.

In this study, we have demonstrated in preclinical models the safety and immunogenicity of recombinant vaccinia viruses expressing SARS-CoV-2 virus spike protein. All three of the prime-boost vaccination regimens with v-NY-S and MVA-S recombinant viruses elicited strong and long-lasting neutralizing antibody responses against SARS-CoV-2, and also generated a T H 1-biased T cell response that can promote pathogen clearance. Importantly, we have demonstrated that our vaccination regimens protected Syrian hamsters (representing an appropriate animal model of SARS-CoV-2-induced respiratory disease in human) from weight loss, elicited rapid clearance of SARS-CoV-2 virus, and reduced immune infiltrates in lung tissue. Previous studies have revealed that virus shedding is often associated with a high viral titer in lung tissues [42, 54, 68] . Bricker et al. (2021) showed that virus titers in vaccinated hamsters were cleared by day 3, and no virus shedding was detected in nasal swabs even as early as day 2 [68] . Furthermore, Liu et al. (2021) found that vaccinated transgenic mice did not shed virus as early as day 2 when virus was cleared from the lungs [42]. Since virus was cleared from the lung tissue of our prime-boost vaccinated animals, it is likely that virus shedding in these animals is limited.

When we compared data from male versus female hamsters in terms of weight loss and virus replication in lungs, we did not observe noticeable sex-associated differences in these hamsters after challenge with SARS-CoV-2 virus. Interestingly, Dhakal et al. (2021) reported that hamsters of both sexes exhibited similar weight loss, virus titers in lungs and cytokine response in the first 5-7 days after SAS-CoV-2 challenge [74] . However, they also showed that, starting from day 7 up to 4 weeks, female hamsters developed greater antibody responses and . (B) . Pseudovirus neutralization assays of the 1˚sera collected 2 weeks after vaccine priming in hamsters. PBS control (n = 4); vNY1 (n = 5); and vNY5 (n = 5). Data represented as mean ± SD. The recovered from weight loss faster than male hamsters [74] . Because all our experiments were terminated within 1 week after SARS-CoV-2 challenge it could explain a lack of sex-associated difference in our experiments.

Hamster is a good animal model of SARS-CoV-2 with several advantages. It is suitable to study virus replication and transmission by contact and aerosols [54, 75] . Most of hamsters infected with SARS-CoV-2 do not die, which is consistent with human infections, and the pathological features of the lungs in the infected animals resemble those observed in COVID-19 patients [56, 76, 77] . Hamster is relatively low cost when compared with other animal models, such as ferrets [78] and non-human primates [79] , and has been shown to mount an effective antibody response that clears virus within one week, making it a suitable model to study vaccine efficacy and antiviral drugs [54, 56, 80] . On the other hand, several limitations of the hamster model exist. SARS-CoV-2 infection in humans affects multiple organ systems including the heart, kidneys, liver, spleen and large intestine [81, 82] whereas in hamsters live virus mainly replicates in respiratory tracts with little evidence of infectious virus in other organs, despite the detection of viral RNA in non-respiratory tissues [55, 83] . Furthermore, a lack of hamster-specific biological reagents makes it difficult to characterize immune responses and the mechanisms of pathogenesis in hamsters.

A successful vaccine against SARS-CoV-2 should stimulate both humoral and cellular immune responses to inhibit virus replication and prevent disease in the host [84] . In both mouse and hamster model our prime-boost immunization with MVA-S and v-NY-S generated high titers of neutralizing antibodies. Evidence from preclinical studies in nonhuman primates and hamsters indicted that vaccine-induced SARS-CoV-2 neutralizing antibodies correlate with protection against lung infection and clinical disease [19, 55, 85] . While it is difficult to study T-cell immune response in hamsters, our immunization regiments induced T H 1-biased immune response and effector memory CD8 + T cells in mice, consistent with other studies using MVA-based SARS-CoV-2 vaccines [41-43, 86]. Interestingly, Tan, et al (2021) reported that early induction of interferon-γ secreting SARS-CoV-2 specific T cells correlates with mild disease and rapid virus clearance, implying an important role of T cell immunity in host protection [87] . How to improve a SARS-CoV-2 vaccine to induce a coordinated B and T responses will be of great importance in the future.

SARS-CoV-2 vaccines developed by Moderna, Pfizer/BioNTech, Novavax and Janssen Pharmaceutical companies expressed a designed SARS-CoV-2 spike protein, S-2P, which contain two proline substitutions at K986 and V987 to stabilize the prefusion conformation of spike protein [19, 85, 88, 89] . It is thought the S-2P design could improve protein stability and elicit high titers of neutralizing antibodies [19, 85, 88, 89] . We did not modify the spike protein in our recombinant virus constructs primarily because of two reasons: (i) Vaccinia viral promoters are known to be much stronger than cellular promoters [90, 91] so the spike protein abundance and stability may not be a concern. (ii). We think that the natural spike protein conformation may provide a large repertoire of antigenic epitopes to generate neutralizing antibodies against SARS-CoV-2 virus. Our neutralizing antibodies induced strong neutralizing 

Vaccinia virus as a SARS-CoV-2 vaccine vector titers, supporting that rationale. Besides, Tscherne et al (2021) constructed a vaccinia MVA-SARS-2-S vaccine that expresses a native SARS-CoV-2 spike protein and their results also showed high neutralizing antibodies were induced [86] . Moreover, the AstraZeneca vaccine, which lacks pre-fusion 2P stabilization, provided sufficient protection during clinical trials [92, 93] . It is intriguing that a new version of spike modification known as HexaPro, that contains 

Vaccinia virus as a SARS-CoV-2 vaccine vector six proline substitutions to further stabilize the pre-fusion S protein, was reported [94] . Whether HexaPro represents a promising antigen for vaccine design will be interesting to know in the future.

While we were testing our vaccination regimens, several research groups published studies showing that MVA-based vaccines provided protection against SARS-CoV-2 infection in hACE2 transgenic mice [41, 86, 95] and macaques [43] . The results of our recombinant MVA-S-based vaccines are consistent with those findings. Our study further explores the utility of the replication-competent v-NY strain, revealing that it could prove just as promising as the MVA strain in tackling SARS-CoV-2. The MVA strain that is growth-restricted in mammalian cells has been widely used in vaccine clinical studies due to its safety features. In contrast, v-NY was originally isolated and developed as a replicating vaccinia vector [96] . A plaque-purified New York City Board of Health strain of vaccinia virus was established from a commercial preparation of smallpox vaccine (Dryvax) via three successive rounds of plaquepurification in BSC-40 cells. A master seed stock of this virus was prepared in human diploid MRC-5 cells, which was then used as the parental virus (v-NY) to construct a recombinant virus expressing the envelope glycoproteins of HIV-1 (HIVAC-1e) later used for FDAapproved clinical trials [44] . Since then, master seed stocks of v-NY have been extensively characterized in terms of sterility, mycoplasma, adventitious viruses, plaque morphology, neutralization by vaccinia-specific monoclonal and polyclonal antisera, neurovirulence and 

Vaccinia virus as a SARS-CoV-2 vaccine vector genome restriction analysis [44] . Unlike NYVAC [97] , which is a highly attenuated virus constructed from the Copenhagen strain of vaccinia virus by specific genetic deletions, v-NY is a replication-competent virus and has not gone through any "attenuation protocol", such as the repeated passages for MVA. The in vitro and in vivo characteristics of v-NY are similar to its parent virus, the New York City Board of Health strain of smallpox vaccine [44] [45] [46] [47] . It is well known that insertion of a foreign gene into the tk locus of vaccinia viral genome such as v-NY will result in further attenuation of vaccinia virus virulence in mice [31] . In terms of safety profile, the recombinant v-NY virus (HIVAC-1e) has been tested in Phase I and II studies [46, 47] . Moreover, v-NY has been used as a control virus in many animal studies and, in all cases, the elicited responses appear very similar to how smallpox vaccines behave in humans [44, 45, 98, 99] .

There are several reasons why we elected to conduct v-NY-S inoculation via skin scarification. First, Langerin + dermal dendritic cells have been shown to effectively present antigen upon skin scarification with vaccinia virus [100] . Secondly, more antibodies are generated upon scarification than via intramuscular inoculation [101] . Thirdly, given experience with the global smallpox vaccination program, skin scarification by means of a bifurcated needle to prick the skin 15 times within a few seconds is a convenient and efficient way to inoculate a large human population during a pandemic. It is possible that for people displaying acute skin breaks such as acne or suffering chronic skin conditions such as eczema or atopic dermatitis, the side-effects may be more serious and should be taken into consideration. In addition, the inoculation site on the arm should be properly cared for so that the virus does not spread. Overall, the availability of both recombinant MVA and v-NY viruses expressing SARS-CoV-2 S protein allows studies to determine whether genetic properties of the viral vector may modulate immune responses leading to differential vaccine efficacies. To this end, it may be worth thinking that a better "placebo vaccine" control than PBS alone would be supernatants of cells that do not express the spike construct but that are prepared the same way as the vaccine. These preparations would contain a secretome including extracellular vesicles and other xenogeneic materials that might contribute to responses like cytokines, albeit presumably non-specific. It will be useful to include such controls in the future experiments.

Most SARS-CoV-2 vaccines currently on the market require a two-dose prime-boost vaccination program to generate sufficient protective immunity [12, 18, 20, 23, [102] [103] [104] [105] [106] [107] . Several Adenovirus-based vaccines (such as ChAdOx) were demonstrated as quite effective following two dosages [19, 20, 55, [108] [109] [110] , though single immunization is sufficient for the Ad26. COV2.S vaccine [19] . Because the fast rise of SARS-CoV-2 variants whether these vaccines can adequately control the COVID pandemic remains unclear. As the stability of currently available COVID vaccines depends on different temperatures of the "cold chain" for storage and transportation, reliance on these vaccines alone for global vaccination may be difficult. In this context, the stability of the lyophilized smallpox vaccine, from which the v-NY vector was derived, may present certain advantages. Thus, these findings from deployment of our recombinant v-NY-S and MVA-S vaccine candidates in a prime-boost vaccination regimen may represent a very useful approach to tackling SARS-CoV-2 infections globally.

Eight-week-old female C57BL/6 mice (Charles River strain) were purchased from BioLASCO Taiwan Co. Ltd. Eight-week-old male and female Syrian hamsters (Mesocricetus auratus) were purchased from the National Laboratory Animal Center, Taiwan. All animal protocols were approved by the Institutional Animal Care and Utilization Committee of Academia Sinica and were conducted in strict accordance with the guidelines on animal use and care of the Taiwan National Research Council's Guide. Immunization and blood collection from animals were performed under isoflurane anesthesia. Animals were sacrificed with carbon dioxide at the end-point of the experiment and all precautions were taken to minimize the suffering to the animals throughout the study.

BSC40 cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) (Gibco) and 1% penicillin-streptomycin (PS) (Gibco). BHK21 cells were cultured in RPMI medium supplemented with 10% FBS and 1% PS. HuTK-143 cells were cultured in MEM medium supplemented with 10% FBS and 1% PS. The v-NY strain of vaccinia virus was grown on BSC40 or HuTK-143 cells as described previously [96, 98, [111] [112] [113] [114] . The MVA strain of vaccinia virus (VR-1508, ATCC) was grown on BHK21 cells. SARS-CoV-2 TCDC#4 (hCoV-19/Taiwan/4/2020) is a local isolate and it was propagated on Vero-E6 cells. All antibodies and reagents are listed in Table 1 below.

To generate recombinant vaccinia viruses expressing SARS-CoV-2 S protein (Isolate Wuhan-Hu-1, NC_045512), a human codon-optimized open reading frame (ORF) encoding fulllength SARS-CoV-2 S protein was inserted into a pSC11 plasmid and under regulatory control 

Vaccinia virus as a SARS-CoV-2 vaccine vector by an early and late p7.5k promoter to obtain pSC11-S plasmid [115] . The pSC11-S plasmid was transfected into HuTK-143 cells infected with the wild type v-NY virus strain. Lysates were then harvested for multiple rounds of plaque purification of the recombinant virus, named v-NY-S, on HuTK-143 in the presence of 25 μg/ml 5-Bromo-2´-Deoxyuridine (BrdU), as described previously [113] . The recombinant MVA strain expressing SARS-CoV-2 S protein, MVA-S, was generated as described for v-NY-S except that BHK21 cells were used and plaque purification was performed in the presence of X-gal (150 μg/ml). Both MVA-S and v-NY-S were subsequently amplified in roller bottles, and the virus stocks were partially purified using a 36% sucrose gradient and titrated prior to use, as described previously [116] . Images were taken using a Zeiss LSM 710 confocal microscope with a 63x objective lens, as described previously [117] .

Eight-week-old female C57BL/6 mice were housed in the Animal Facility of Academia Sinica (Taipei, Taiwan) for at least 3 days prior to vaccination experiments. We primarily used three regimens of two-dosage prime/boost immunization (depicted in Fig 2A) : (1) As immunization controls, PBS buffer was used as a placebo vaccine for both priming and boosting shots. Blood was collected from immunized mouse cheeks 4 weeks after priming and 2 weeks after boosting, as described previously [118, 119] . Sera were prepared from blood and saved at -80˚C until use.

Eight-week-old male and female Syrian hamsters were housed in the Animal Facility of Academia Sinica (Taipei, Taiwan) for at least 3 days prior to vaccination experiments. We used three regimens of two-dosage prime/boost immunization (depicted in Fig 2A) : (1) MVA5/MVA1-intramuscular (i.m.) inoculation of MVA-S in the right hind limb at 5x10 7 PFU/animal, followed by an i.m. boost 4 weeks later of 1x10 7 PFU/animal of MVA-S virus; (2) vNY1/MVA1tail scarification (t.s) of v-NY-S at 1x10 7 PFU/animal, followed by an i.m. boost 4 weeks later of 1x10 7 PFU/animal of MVA-S virus into the right hind limb; and (3) vNY5/MVA1-t.s. of v-NY-S at 5x10 7 PFU/animal, followed by an i.m. boost 4 weeks later of 1x10 7 PFU/animal of MVA-S virus into right hind limb. As immunization controls, PBS buffer was used as a placebo vaccine for both priming and boosting shots. Blood was collected from immunized hamster gingival veins 4 weeks after priming and 2 weeks after boosting, as described previously [118, 119] . Sera was prepared from blood and saved at -80˚C until use.

To measure SARS-CoV-2 S protein expression in cells infected with recombinant viruses, BSC40 and BHK21 cells (5x10 5 ) were infected with v-NY-S and MVA-S, respectively, at an MOI of 5 PFU/cell and incubated for 12 h prior to cell harvesting. Cells were lysed with sample buffer and proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were then transferred to nitrocellulose membranes (BioRad) using a wet transfer apparatus (Bio-Rad). The membranes were blocked in 5% non-fat milk solution at room temperature (r.t.) for 1 h and incubated overnight with SARS-CoV-2 spike S2 mouse mAb (GTX632604, 1:1000 dilution) at 4˚C. The blots were then washed three times with PBST (PBS containing 0.1% Tween-20), incubated at r.t. with HRP goat anti-mouse IgG Ab (31430, 1:20,000) for 1 h and developed using a Western Lightening Enhanced Chemiluminescence kit (PerkinElmer) according to the manufacturer's protocol.

To test reactivity of immunized mouse and hamster sera to SARS-CoV-2 spike protein, the extracellular domain of spike protein from residue 14 to 1209, consisting of S1 and S2 but without the transmembrane domain, was expressed in HEK 293 cells and subsequently purified. The purified spike protein contained human complex type glycans, and exists as a trimer in solution with an apparent molecular weight between 170 to 235 kDa on SDS-PAGE (monomer), and~600 kDa (trimer) on Superose 6 size-exclusion chromatography. Purified spike protein (20 ng/well) was separated by SDS-PAGE, transferred to nitrocellulose membranes and blocked in 5% non-fat milk solution at r.t. as described above. The membrane was separated into multiple strips and each strip was incubated overnight with individual sera collected from immunized mice (1:100 dilution) or hamsters (1:50) at 4˚C. These blots were then washed three times with PBST, incubated at r.t. with HRP goat anti-mouse (31430, 1:20,000) or HRP goat anti-hamster (PA1-28823, 1:5,000) antibodies for 1 h at r.t. and then developed using a Western Lightning Enhanced Chemiluminescence kit (PerkinElmer) according to the manufacturer's protocol.

To detect spike protein expression on the surface of cells infected with MVA-S or v-NY-S, BSC40 and BHK21 cells (5x10 5 ) were infected with v-NY-S and MVA-S, respectively, at an MOI of 5 PFU/cell and incubated for 12 h, before being detached via treatment with 2 mM EDTA in PBS. Cells were incubated with SARS-CoV-2 anti-RBD antibody (40592-T62, 1:500) at 4˚C for 1 h. The cells were then washed with FACS buffer (PBS containing 2% FBS), stained with FITC-conjugated goat anti-Rabbit IgG Ab (F1262, 1:500) for 1 h at 4˚C, washed with FACS buffer and analyzed by flow cytometry (BD LSR-II, BD Biosciences).

To detect anti-spike antibody in the sera of immunized mice and hamsters, SF9 insect cells were infected with either wild type baculovirus (WT-BAC) or a recombinant baculovirus (S-BAC) that expressed a chimeric SARS-CoV-2 S-gp64 protein in which the transmembrane and C-terminal regions of S protein were replaced by the transmembrane and C-terminal regions of baculovirus GP64 so that the S-gp64 fusion protein would be expressed on insect cell surfaces. These cells were cultured for 48 h before incubating with mouse (1:100 dilution) or hamster (1:20 dilution) serum in FACS buffer for 1 hour on ice. After two washes with FACS buffer, the cells were incubated with Cy5-Goat anti-mouse IgG Ab (115-175-146, 1:500) or FITC-Goat anti-hamster IgG Ab (11-4211-85, 1:100) for 30 min on ice, washed twice, resuspended in FACS buffer containing propidium iodide, and then analyzed by flow cytometry (BD LSR-II).

Lentiviral vectors pseudotyped with spike protein of wild type SARS-CoV-2 and SARS-CoV-2 variants of concern (VOC) ( Table 2 ) were generated and titered by the National RNA Technology Platform and Gene Manipulation Core, Academia Sinica, Taipei, Taiwan. Neutralization assays on pseudotyped virus were performed by the same core facility as described previously [120] , but with minor modifications. In brief, 1,000 units of the pseudotyped lentivirus with SARS-CoV-2 S protein were incubated at 37˚C for 1 h with serially-diluted sera obtained from vaccinated animals. The mixture was then added to HEK-293T cells expressing human ACE2 receptor (10 4 cells/well of a 96-well plate) and incubated for 24 h at 37˚C. This cell culture was then replaced with 100 μl of fresh DMEM plus 10% FBS, and the cells were incubated for another 48 h before undergoing luciferase assay. The reciprocal dilution of serum required for 50% inhibition of virus infection (ND 50 ) was assessed by measuring luciferase intensity.

Serially diluted antibodies from immunized mice or hamsters were incubated at 37˚C for 1 h with 100 TCID 50 SARS-CoV-2 TCDC#4 (hCoV-19/Taiwan/4/2020). The mixtures were then added to pre-seeded Vero E6 cells for a 4-day incubation. Cells were fixed with 10% formaldehyde and stained with 0.5% crystal violet for 20 min. The plates were washed with tap water and scored for infection. The 50% protective titer was calculated according to the Reed & Muench Method [121] .

Immunoglobulin ELISA was performed as described previously [17] with some modifications. Recombinant SARS-CoV-2 S protein (10 ng/well) was coated onto a 96-well plate (Costar assay plate, Corning, 3369) for 24 h at 4˚C. The plates were then washed with PBST and blocked with 1% BSA in PBS solution for 1 h, followed by washes with PBST. Coated plates was added and the plates were read at an optical density of 450 nm using an ELISA reader. End-point titers were calculated as the serum dilutions that emitted an optical density (O.D) greater than four times the background level (secondary antibody only), as described previously [17] .

ELISpot assays to monitor cytokine levels in splenocytes stimulated with a SARS-CoV-2 spike peptide pool were performed essentially as described previously [109, 122] . In brief, spleens were collected from immunized mice four weeks after vaccine boosting. We mixed 4x10 5 splenocytes with a peptide pool of SARS-CoV-2 S protein sequences (Miltenyi Biotech, 130-126-700) at 1 μg/ml concentration in 100 μl medium (RPMI + 10% FBS + 1% PS), and then incubated them for 24 h at 37˚C in ELISpot plates (MABTECH) precoated with IFN-γ (3321-4AST-2), IL-2 (3441-4APW-2), IL-4 (3311-4APW-2), IL-6 (3361-4APW-2) or TNF-α (3511-4APW-2). Cells were then washed with 5x PBS and the ELISpots were developed according to the manufacturer's protocol and quantified using an AID vSpot machine.

Flow cytometric analyses of Tem cells were performed as described previously [16] with minor modifications. Splenocytes were isolated from immunized mice at 4 weeks after vaccine boosting. After depleting red blood cells with Ammonium-Chloride-Potassium (ACK) lysis buffer, splenocytes were stimulated with 1 μg/ml of a SARS-CoV-2 spike-specific peptide pool (Miltenyi Biotech, 130-126-700) in medium (RPMI + 10% FBS + 1% PS) for 2 h at 37˚C. The cells were subsequently washed twice with FACS buffer, and then incubated with an antibody cocktail including anti-CD3-PE/Cyanine7, anti-CD4-FITC, anti-CD8-Pacific blue, anti-CD44-PE and anti-CD62L-APC for 15 min on ice. The cells then underwent fluorescence-activated cell sorting (FACS) analyses, whereby CD4 + or CD8 + subpopulations were first gated from total splenocytes, and then further gated for CD44 + CD62Las Tem cells. Dead cells were stained with eFluor 506 viability dye (eBioscience). Cells were acquired using a BD LSR II (BD Biosciences) flow cytometer and data analyses were performed with FlowJo 8.7 software.

Syrian hamsters were immunized according to one of the three prime-boost vaccination regimens described above, anesthetized, with Zoletil-50 (50mg/kg) and then intranasally (i.n) challenged with 1x10 5 PFU of SARS-CoV-2 TCDC#4 (hCoV-19/Taiwan/4/2020, GISAID accession ID: EPI_ISL_411927) (lot: IBMS20200819, 8x10 5 PFU/ml) in a volume of 125 μl. All animals were weighed daily after SARS-CoV-2 challenge. At 3 and 7 days post infection (d.p. i.), lungs were harvested for SARS-CoV-2 virus titer determination, viral RNA quantification and histopathological examination. Differences in body weight between experimental groups of animals were analyzed statistically using a two-tailed unpaired Student's t test.

The middle, inferior, and post-caval lobes of hamsters at 3 and 7 days post challenge with SARS-CoV-2 were homogenized in 4ml of DMEM with 2% FBS and 1% PS using a homogenizer. Tissue homogenate was centrifuged at 15,000 rpm for 5 min and the supernatant was collected for live virus titration. Briefly, 10-fold serial dilutions of each sample were added in quadruplicate onto a Vero E6 cell monolayer and incubated for 4 days. Cells were then fixed with 10% formaldehyde and stained with 0.5% crystal violet for 20 min. The plates were washed with tap water and scored for infection. The fifty-percent tissue culture infectious dose (TCID 50 )/ml was calculated according to the Reed & Muench Method [121] .

To measure the RNA levels of SARS-CoV-2, specific primers targeting nucleotides 26,141 to 26,253 of the SARS-CoV-2 envelope (E) gene were used for real-time RT-PCR, as described previously [123] , forward primer E-Sarbeco-F1 (5'-ACAGGTACGTTAATAGTTAATAGCGT-3'), reverse primer E-Sarbeco-R2 (5'-ATATTGCAGCAGTACGCACACA-3'), probe E-Sarbeco-P1 (5'-FAM-ACACTAGCCATCCTTACTGCGCTTCG-BBQ-3' 

The left lung of each hamster at 3 and 7 days post challenge with SARS-CoV-2 was removed and fixed in 4% paraformaldehyde for 1 week. The lung samples were then embedded, sectioned, and stained with Hematoxylin and Eosin (H&E), followed by microscopic examination. Immunohistochemical staining was performed with a monoclonal rabbit anti-SARS-CoV/SARS-CoV-2 nucleocapsid (NP) antibody (1:1000, 40143-R001, Sino Biological), followed by incubation with Dako EnVision+ System HRP. Brownish signals were subsequently developed upon addition of 3,3' diaminobenzidine (DAB) and counterstained with hematoxylin. Images were photographed using a Zeiss Axioimager-Z1 microscope with 4x and 20x objective lenses.

Statistical analyses were conducted using Student's t test in Prism (version 9) software (Graph-Pad). For multiple comparisons, the p values were adjusted by the "fdr" method using the "p. adjust" function in R v4.0.4. Adjusted p values <0.05 were considered statistically significant. � p<0.05; �� p<0.01; ��� p<0.001; ���� p<0.0001. 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Characteristics of SARS-CoV-2 and COVID-19

Cell entry mechanisms of SARS-CoV-2

Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Viral targets for vaccines against COVID-19

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Candidate Targets for Immune Responses to 2019-Novel Coronavirus (nCoV): Sequence Homology-and Bioinformatic-Based Predictions

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2

A Thermostable mRNA Vaccine against COVID-19

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

ChA-dOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

SARS-CoV-2 vaccines in development

Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

SARS-CoV-2 Causes a Systemically Multiple Organs Damages and Dissemination in Hamsters

Regeneration Profiles of Olfactory Epithelium after SARS-CoV-2 Infection in Golden Syrian Hamsters

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the

Animal models for COVID-19

Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility

Oral SARS-CoV-2 Inoculation Establishes Subclinical Respiratory Infection with Virus Shedding in Golden Syrian Hamsters

A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters

Protection against reinfection with D614-or G614-SARS-CoV-2 isolates in golden Syrian hamster

Age-Dependent Progression of SARS-CoV-2 Infection in Syrian Hamsters

Heterologous primeboost COVID-19 vaccination: initial reactogenicity data

Mix-and-match COVID vaccines: the case is growing, but questions remain

Mix-and-match COVID vaccines trigger potent immune response

Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden Syrian hamster model. bioRxiv

Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

COVID-19 and multiorgan failure: A narrative review on potential mechanisms

COVID-19 and Multiorgan Response

SARS-CoV-2 infection in the Syrian hamster model causes inflammation as well as type I interferon dysregulation in both respiratory and non-respiratory tissues including the heart and kidney

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Vaccinia virus: a selectable eukaryotic cloning and expression vector

Vaccinia virus as an expression vector

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in Syrian hamster model

Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97

NYVAC: a highly attenuated strain of vaccinia virus

Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus

Oral Immunization with Recombinant Vaccinia Virus Prime and Intramuscular Protein Boost Provides Protection against Intrarectal Simian-Human Immunodeficiency Virus Challenge in Macaques

Langerin(+) Dermal DC, but Not Langerhans Cells, Are Required for Effective CD8-Mediated Immune Responses after Skin Scarification with Vaccinia Virus

Comparative Efficacy of Intramuscular and Scarification Routes of Administration of Live Smallpox Vaccine in a Murine Challenge Model. Vaccine

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

A thermostable mRNA vaccine against COVID-19

Phase 1-2 Trial of a SARS

Recombinant Spike Protein Nanoparticle Vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques

Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice

Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins

Processing, Assembly, and Immunogenicity of Human-Immunodeficiency-Virus Core Antigens Expressed by Recombinant Vaccinia Virus

Generation of Recombinant Vaccinia Viruses

Preparation of Cell Cultures and Vaccinia Virus Stocks

Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques

Bioinformatics Analysis of Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein

Integrin beta1 mediates vaccinia virus entry through activation of PI3K/Akt signaling

A rapid, simple, and humane method for submandibular bleeding of mice using a lancet

The gingival vein as a minimally traumatic site for multiple blood sampling in guinea pigs and hamsters

Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19

Determination of 50% endpoint titer using a simple formula

CoVaccine HT Adjuvant Potentiates Robust Immune Responses to Recombinant SARS-CoV-2 Spike S1 Immunization

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

We thank Sue-Ping Lee of the Imaging Core Facility, Ya-Min Lin of the FACS Core Facility and Kun-Hai Yeh of Bioinformatics Core facility at the Institute of Molecular Biology and Data Science Statistical Cooperation Center-Statistical Clinics at Acadmia Sinica. We also thank Brad Cleveland for advice and assistance with the v-NY vector.